Dynamic evaluation of ¹³¹I therapy for differentiated thyroid carcinoma and analysis of factors influencing the excellent response

ObjectiveTo analyze the risk factors influencing the excellent response(ER) in differentiated thyroid carcinoma(DTC) patients without distant metastasis after ¹³¹I therapy.

MethodsOne hundred and sixty patients treated with ¹³¹I treatment were followed for 24 months, and the efficacy response of all cases after 3, 6, 12 and 24 months of treatment were evaluated.The clinicopathological differences of patients with different therapeutic stratification were analyzed using χ² test, Fisher exact test and Mann Whitney U test, and the logistic regression analysis and ROC curve analysis were used to explore the factors affecting ER.

ResultsCompared with the initial evaluation, the ER rate at the final evaluation significantly increased(P < 0.01).The proportion of patient with younger age, lower ps-Tg level, ¹³¹I treatment times < 3, ¹³¹I total dose < 500 mCi, low initial risk stratification and initial TNM stage Ⅰ-Ⅱ in ER group were higher those in non-ER(P < 0.05 to P < 0.01).The results of logistic multiple regression analysis showed the serum ps-Tg was a protective factor affecting end-stage ER(OR=0.942, P < 0.01).The areas under ROC curve of the relationship between ps-Tg and initial ER, and final ER were 0.884 and 0.762, respectively.The optimal critical values of predicting non-ER were 16.62 ng/mL and 46.37 ng/mL(P < 0.01).

ConclusionsThe efficacy of ¹³¹I in the treatment of DTC patients without distant metastasis is significant.The serum ps-Tg is of great value in predicting the initial and final evaluation of curative effects.